Sacituzumab govitecan for advanced ovarian cancer with TROP-2
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a drug called IMMU-132 (sacituzumab govitecan) for women with advanced or recurrent ovarian cancer that has come back after platinum-based chemotherapy. The drug targets a protein called TROP-2 found on tumor cells, which may help stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have advanced or recurrent ovarian, fallopian tube, or primary peritoneal cancer confirmed by biopsy.
- Your tumor has high levels of TROP-2 (tested on a tissue sample).
- Your cancer has come back or gotten worse after at least one round of platinum-based chemo, or after three rounds if more than 6 months have passed.
- You have measurable disease or clear signs of progression according to standard criteria.
- You have not taken topoisomerase I inhibitors before (like irinotecan).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
This study looks at how well the drug Sacituzumab Govitecan works in real-life settings for people with certain types of advanced breast cancer that have not responded to prior treatments.
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
This trial tests a drug called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma that has already been treated with chemotherapy and immunotherapy. The drug targets a protein called Trop-2 on cancer cells to try to stop tumor growth.
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.